Skip to main content

Second-Best Stocks Offer Top-Notch Growth

Fund manager Susan Kempler says stock investors should look past industry leaders and consider companies right behind them, such as generic drugmaker Mylan and shipping company UPS.

SAN FRANCISCO (TheStreet) -- Susan Kempler, manager of the TIAA-CREF Growth & Income Fund (TIIRX) - Get TIAA-CREF Growth & Inc Retail Report, says stock investors should look past industry leaders and consider companies right behind them, such as generic drugmaker Mylan (MYL) - Get Viatris, Inc. Report and shipping company UPS (UPS) - Get United Parcel Service, Inc. Class B Report.

The $1.8 billion fund, which has earned five stars from


(MORN) - Get Morningstar, Inc. Report

, has returned 6.8% annually during the past five years, better than 97% of its large-cap blend peers. The fund has climbed 8.2% this year, lagging half of its peers. Top holdings include

Exxon Mobil

(XOM) - Get Exxon Mobil Corporation Report



(AAPL) - Get Apple Inc. Report



(MSFT) - Get Microsoft Corporation Report


Welcome to


Scroll to Continue

TheStreet Recommends

Fund Manager Five Spot, where America's top mutual fund managers give their best stock picks and views on the market in a five-question format.

Why do you like the health care sector and generic drug stocks in particular?


If you look back to last year when regulatory reform was an overhang for the group, the companies were trading at roughly a 50% discount to the market multiple. We thought they were too cheap given the fundamental outlook for the companies, the aging population and their ability to generate cash flow going forward.

As for generics, we have $150 billion worth of branded drugs going off patent around 2012 which should translate into approximately $30 billion of revenues for the generic drug manufacturers over the next 5 years. In addition, within the United States, which is the biggest generic drug market in the world, we are seeing pricing stability and consolidation.

Why is Mylan your top pick among generic drugmakers?


We bought the stock back in April of 2008 when they bought the generic drug division of

Merck KGaA

. This gave them a global platform that we believe is important going forward. Previously, they had been mostly domestic based.

Secondly, it was trading at a significant discount to

Teva Pharmaceutical Industries

(TEVA) - Get Teva Pharmaceutical Industries Ltd. Report

, which is seen as the leader in the generic industry. We thought Mylan's ability to integrate that acquisition and show synergies made that five multiple discount unfounded.

Outside of health care, you like


(HAL) - Get Halliburton Company Report

in the oil services industry. Why that one?


When we bought the stock in 2008 it was trading at a five-point multiple discount to


(SLB) - Get Schlumberger NV Report

, which is the leading player in the industry. The company's new management, which really came in around the beginning of the decade, has really improved its offerings to Halliburton clients. They grew their technology base and now they are able to offer bundled products, becoming more of a one-stop shop.

In addition, they have been more defensive during the downturn for oil services, holding up a little better in terms of revenue declines and margin declines. And they have been showing improving returns on invested capital. The proof of the pudding was their win with

Saudi Aramco

, which is giving them a really nice runway to revenue growth going forward.

Another company you like is UPS. Why UPS as opposed to


(FDX) - Get FedEx Corporation Report



UPS is leveraged, just like FedEx and the other capital goods companies, to an improving economy and we like that first and foremost. Secondly, what we are seeing is that because of its renegotiated contracts with the unions, its cost structure is much better. Analysts on the sell side are underestimating its ability to leverage that going forward. We also like the pricing stability in the sector because


is no longer out there destroying prices for everybody.

Do the fraud allegations at

Goldman Sachs

(GS) - Get Goldman Sachs Group, Inc. Report

mean investors should avoid financials?


I'm not sure about the need to fully avoid the financials. It's hard to speculate on the outcome of the Goldman Sachs situation. I think that if you are a bottoms-up stock picker like we are, looking at stocks in detail, then you can find financials to fit any environment. I do think there will be more regulatory reform for these companies, and that will be first and foremost in people's minds when they are thinking of the financial sector.


Reported by Gregg Greenberg in New York


Before joining, Gregg Greenberg was a writer and segment producer for CNBC's Closing Bell. He previously worked at FleetBoston and Lehman Brothers in their Private Client Services divisions, covering high net-worth individuals and midsize hedge funds. Greenberg attended New York University's School of Business and Economic Reporting. He also has an M.B.A. from Cornell University's Johnson School of Business, and a B.A. in history from Amherst College.